Gene therapy for HIV-1 infection: Are lethal genes a valuable tool?

Cellular and Molecular Biology

Volumn 51, Issue 1, 2005, Pages 93-101

  Luque, F ^a   Oya, R ^a   Macias D ^a   Saniger, L ^a  

^a UNIVERSITY OF JAÉN   (Spain)

Author keywords

Gene therapy; HIV 1; Lentiviral vectors; Lethal genes

Indexed keywords

ACICLOVIR; BACTERIAL TOXIN; GAG PROTEIN; GANCICLOVIR; GENE PRODUCT; LENTIVIRUS VECTOR; POL PROTEIN; THYMIDINE KINASE; VIF PROTEIN; VIRUS ENVELOPE PROTEIN; VPR PROTEIN; VPU PROTEIN;

CAT DISEASE; CELL KILLING; CELL PROTECTION; ENVELOPE GENE; GENE EXPRESSION; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LENTIVIRINAE; LETHAL GENE; MOLONEY LEUKEMIA ONCOVIRUS; NONHUMAN; REVIEW; SAFETY; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN VIRUS; STRUCTURAL GENE; VIRAL GENE THERAPY; VIRUS; VIRUS REPLICATION;

ANIMALS; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; VIRUS REPLICATION;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; MOLONEY MURINE LEUKEMIA VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN VIRUS;

EID: 30744458345     PISSN: 01455680     EISSN: 1165158X     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Anderson, J., Banerjea, A., Planelles, V. and Akkina, R., Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. AIDS Res. Hum. Retroviruses 2003, 19: 699-706.
2. Bahner, I., Kearns, K., Coutinho, S., Leonard, E.H. and Kohn, D.B., Infection of human marrow stroma by human immunodeficiency virus-1 (HIV-1) is both required and sufficient for HIV-1-induced hematopoietic suppression in vitro: demonstration by gene modification of primary human stroma. Blood 1997, 90: 1787-1798.
3. + hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture. J. Virol. 1996, 70: 4352-4360.
4. Bahner, I., Zhou, C., Yu, X.J., Hao, Q.L., Guatelli, J.C. and Kohn, D.B., Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. J. Virol. 1993, 67: 3199-3207.
5. + hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Mol. Ther. 2000, 1: 244-254.
6. Bai, J., Sui, J., Zhu, R.Y., Tallarico, A.S., Gennari, F., Zhang, D. and Marasco, W.A., Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J. Biol. Chem. 2003, 278: 1433-1442.
7. Bai, X., Chen, J.D., Yang, A.G., Torti, F. and Chen, S.Y., Genetic co-inactivation of macrophage- and T-tropic HIV-1 chemokine coreceptors CCR-5 and CXCR-4 by intrakines. Gene Ther. 1998, 5: 984-994.
8. + progenitor cell-derived macrophages. Mol. Ther. 2003, 8: 62-71.
9. + cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 1997, 89: 2259-2267.
10. Berkhout, B., Silverman, R.H. and Jeang, K.T., Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 1989, 59: 273-282.
11. Bleul, C.C., Farzan, M., Choe, H., Parolin, C., Clark-Lewis, I., Sodroski, J. and Springer, T.A., The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382: 829-833.
12. Blomer, U., Naldini, L., Kafri, T., Trono, D., Verma, I.M. and Gage, F.H., Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 1997, 71: 6641-6649.
13. Bonyhadi, M.L., Moss, K., Voytovich, A., Auten, J., Kalfoglou, C., Plavec, I., Forestell, S., Su, L., Bohnlein, E. and Kaneshima, H., RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication. J. Virol. 1997, 71: 4707-4716.
14. BouHamdan, M., Duan, L.X., Pomerantz, R.J. and Stayer, D.S., Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection. Gene Ther. 1999, 6: 660-666.
15. BouHamdan, M., Stayer, D.S., Wei, D., Mukhtar, M., Duan, L.X., Hoxie, J. and Pomerantz, R.J., Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4. Gene Ther. 2001, 8: 408-418.
16. Brady H.J., Miles, C.G., Pennington, D.J. and Dzierzak, E.A., Specific ablation of human immunodeficiency virus Tat-expressing cells by conditionally toxic retroviruses. Proc. Natl. Acad. Sci. USA 1994, 91: 365-369.
17. Brenner, B., Wainberg, M.A., Salomon, H., Rouleau, D., Dascal, A., Spira, B., Sekaly R.P., Conway B. and Routy J.P., Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study. Int. J. Antimicrob. Agents 2000, 16: 429-434.
18. Browning, C.M., Cagnon, L., Good, P.D., Rossi, J., Engelke, D.R. and Markovitz, D.M., Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy. J. Virol. 1999, 73: 5191-5195.
19. Buchschacher, G.L. Jr. and Wong-Staal, F., Development of lentiviral vectors for gene therapy for human diseases. Blood 2000, 95: 2499-2504.
20. Cagnon, L. and Rossi, J.J., Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts. Antisense Nucl. Acid Drug Dev. 2000, 10: 251-261.
21. Caputo, A., Rossi, C., Bozzini, R., Betti, M., Grossi, M.P., Barbanti-Brodano, G. and Balboni, P.G., Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication. Gene Ther. 1997, 4: 288-295.
22. + cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population. Proc. Natl. Acad. Sci. USA 1992, 89: 182-186.
23. Chadwick, D.R. and Lever, A.M., Antisense RNA sequences targeting the 5′ leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle. Gene Ther. 2000, 7: 1362-1368.
24. Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P.D., Wu, L., Mackay C.R., LaRosa, G., Newman, W., Gerard, N., Gerard, C. and Sodroski, J., The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85: 1135-1148.
25. Chun, T.W., Stuyver, L., Mizell, S.B., Ehler, L.A., Mican, J.A., Baseler, M., Lloyd, A.L., Nowak, M.A. and Fauci, A.S., Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 1997, 94: 13193-13197.
26. Coleman, J.E., Huentelman, M.J., Kasparov, S., Metcalfe, B.L., Paton, J.F., Katovich, M.J., Semple-Rowland, S.L. and Raizada, M.K., Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol. Genomics 2003, 12: 221-228.
27. Cordelier, P. and Strayer, D.S., Conditional expression of alpha(1)-antitrypsin delivered by recombinant SV40 vectors protects lymphocytes against HIV Gene Ther. 2003, 10: 2153-2156.
28. Cordelier, P., Van Bockstaele, E., Calarota, S.A. and Strayer, D.S., Inhibiting AIDS in the central nervous system: gene delivery to protect neurons from HIV. Mol. Ther. 2003, 7: 801-810.
29. Cordelier, P., Zern, M.A. and Strayer, D.S., HIV-1 proprotein processing as a target for gene therapy. Gene Ther. 2003, 10: 467-477.
30. Curiel, T.J., Cook, D.R., Wang, Y., Hahn, B.H., Ghosh, S.K. and Harrison, G.S., Long-term inhibition of clinical and laboratory human immunodeficiency virus strains in human T cell lines containing an HIV-regulated diphtheria toxin A chain gene. Hum. Gene Ther. 1993, 4: 741-747.
31. Davis, B.M., Humeau, L. and Dropulic, B., In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication. Mol. Ther. 2004, 9: 160-172.
32. Dinges, M.M., Cook, D.R., King, J., Curiel, T.J., Zhang, X.Q. and Harrison, G.S., HIV-regulated diphtheria toxin A chain gene confers long-term protection against HIV type 1 infection in the human promonocytic cell line U937. Hum. Gene Ther. 1995, 6: 1437-1445.
33. Dropulic, B. Lentivirus in the clinic. Mol. Ther. 2001, 4: 511-512.
34. Dropulic, B., Hermankova, M. and Pitha, P.M., A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc. Natl. Acad. Sci. USA 1996, 93: 11103-11108.
35. Egelhofer, M., Brandenburg, G., Martinius, H., Schult-Dietrich, P., Melikyan, G., Kunert, R., Baum, C., Choi, I., Alexandrov, A. and von Laer, D., Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J. Virol. 2004, 78: 568-575.
36. Engel, B.C. and Kohn, D.B., Stem cell directed gene therapy. Front. Biosci. 1999, 4: e26-33.
37. Ensoli, B., Barillari, G., Salahuddin, S.Z., Gallo, R.C. and Wong-Staal, F., Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990, 345: 84-86.
38. Felber, B.K., Hadzopoulou-Cladaras, M., Cladaras, C., Copeland, T. and Pavlakis, G.N., rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc. Natl. Acad. Sci. USA 1989, 86: 1495-1499.
39. Feng, Y., Broder, C.C., Kennedy, P.E. and Berger, E.A., HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G-protein-coupled receptor. Science 1996, 272: 872-877.
40. Feng, Y., Leavitt, M., Tritz, R., Duarte, E., Kang, D., Mamounas, M., Gilles, P., Wong-Staal, F., Kennedy, S., Merson, J., Yu, M. and Barber, J.R., Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5. Virology 2000, 276: 271-278.
41. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999, 5: 512-517.
42. Finzi, D., Hermankova, M., Pierson, T., Carruth, L.M., Buck, C., Chaisson, R.E., Quinn, T.C., Chadwick, K., Margolick, J., Brookmeyer, R., Gallant, J., Markowitz, M., Ho, D.D., Richman, D.D. and Siliciano, R.F., Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278: 1295-1300.
43. Fornerod, M., Ohno, M., Yoshida, M. and Mattaj, I.W., CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 1997, 90: 1051-1060.
44. Fraisier, C., Abraham, D.A., van Oijen, M., Cunliffe, V., Irvine, A., Craig, R, and Dzierzak, E.A., Inhibition of Tat-mediated transactivation and HIV replication with Tat mutant and repressor domain fusion proteins. Gene Ther. 1998, 5: 946-954.
45. Fraisier, C., Irvine, A., Wrighton, C., Craig, R. and Dzierzak, E., High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector. Gene Ther. 1998, 5: 1665-1676.
46. Frankel, A.D. and Pabo, C.O., Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988, 55: 1189-1193.
47. Gallo, R.C., Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc. Natl. Acad. Sci. USA 1999, 96: 8324-8326.
48. Garcia, J.A., Wu, F.K., Mitsuyasu, R. and Gaynor, R.B., Interactions of cellular proteins involved in the transcriptional regulation of the human immunodeficiency virus. EMBO J. 1987, 6: 3761-3770.
49. Gervaix, A., Li, X., Kraus, G. and Wong-Staal, F., Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J. Virol. 1997, 71: 3048-3053.
50. Goldstein, H., Pettoello-Mantovani, M., Anderson, C.M., Cordelier, P., Pomerantz, R.J. and Strayer, D.S., Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue. J. Infect. Dis. 2002, 185: 1425-1430.
51. Hammarskjold, M.L., Heimer, J., Hammarskjold, B., Sangwan, I., Albert, L. and Rekosh, D., Regulation of human immunodeficiency virus env expression by the rev gene product. J. Virol. 1989, 63: 1959-1966.
52. Hanawa, H., Hematti, P., Keyvanfar, K., Metzger, M.E., Krouse, A., Donahue, R.E., Kepes, S., Gray, J., Dunbar, C.E., Persons, D.A. and Nienhuis, A.W., Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood 2004.
53. Harrison, G.S., Long, C.J., Curiel, T.J., Maxwell, F. and Maxwell, I.H., Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphtheria toxin A chain gene. Hum. Gene Ther. 1992, 3: 461-469.
54. Harrison, G.S., Long, C.J., Maxwell, F., Glode, L.M. and Maxwell, I.H., Inhibition of HIV production in cells containing an integrated, HIV-regulated diphtheria toxin A chain gene AIDS Res. Hum. Retroviruses 1992, 8: 39-45.
55. Henderson, B.R. and Percipalle, P., Interactions between HIV Rev and nuclear import and export factors: the Rev nuclear localisation signal mediates specific binding to human importin-beta. J. Mol. Biol. 1997, 274: 693-707.
56. + T lymphocytes in vivo. J. Virol. 2003, 77: 7383-7392.
57. Herrmann, C.H. and Rice, A.P. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J. Virol. 1995, 69: 1612-1620.
58. Huang, L., Bosch, I., Hofmann, W., Sodroski, J. and Pardee, A.B., Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J. Virol. 1998, 72: 8952-8960.
59. Jakobsson, J., Ericson, C., Jansson, M., Bjork, E. and Lundberg, C., Targeted transgene expression in rat brain using lentiviral vectors. J. Neurosci. Res. 2003, 73: 876-885.
60. Klug, C.A., Cheshier, S. and Weissman, I.L., Inactivation of a GFP retrovirus occurs at multiple levels in long-term repopulating stem cells and their differentiated progeny. Blood 2000, 96: 894-901.
61. Kordower, J.H., Emborg, M.E., Bloch, J., Ma, S.Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.Y., Palfi, S., Roitberg, B.Z., Brown, W.D., Holden, J.E., Pyzalski, R., Taylor, M.D., Carvey P., Ling, Z., Trono, D., Hantraye, P., Deglon, N. and Aebischer, P., Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000, 290: 767-773.
62. Kyrkanides, S., Miller, J.H. and Federoff, H.J., Systemic FIV vector administration: transduction of CNS immune cells and Purkinje neurons. Mol. Brain Res. 2003, 119: 1-9.
63. Leavitt, M.C., Yu, M., Yamada, O., Kraus, G., Looney D., Poeschla, E. and Wong-Staal, F., Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. Hum. Gene Ther. 1994, 5: 1115-1120.
64. Lee, M.T., Coburn, G.A., McClure, M.O. and Cullen, B.R., Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J. Virol. 2003, 77: 11964-11972.
65. Lee, N.S., Dohjima, T., Bauer, G., Li, H., Li, M.J., Ehsani, A., Salvaterra, P., Rossi, J., Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol. 2002, 20: 500-505.
66. Levy-Mintz, P., Duan, L., Zhang, H., Hu, B., Dornadula, G., Zhu, M., Kulkosky J., Bizub-Bender, D., Skalka, A.M. and Pomerantz, R.J., Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. J. Virol. 1996, 70: 8821-8832.
67. Lewis, P.F. and Emerman, M., Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. 1994, 68: 510-516.
68. Li, C.J., Friedman, D.J., Wang, C., Metelev, V. and Pardee, A.B., Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 1995, 268: 429-431.
69. Lisziewicz, J., Rappaport, J. and Dhar, R., Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression. New Biol. 1991, 3: 82-89.
70. Lisziewicz, J., Sun, D., Smythe, J., Lusso, P., Lori, F., Louie, A., Markham, P., Rossi, J., Reitz, M. and Gallo, R.C., Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc. Natl. Acad. Sci USA 1993, 90: 8000-8004.
71. Lois, C., Hong, E.J., Pease, S., Brown, E.J. and Baltimore, D., Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002, 295: 868-872.
72. Malim, M.H., Hauber, J., Le, S.Y., Maizel, J.V. and Cullen, B.R., The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 1989, 338: 254-257.
73. Martinez, M.A., Gutierrez, A., Armand-Ugon, M., Blanco, J., Parera, M., Gomez, J., Clotet, B. and Este, J.A., Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 2002, 16: 2385-2390.
74. Mautino, M.R., Lentiviral vectors for gene therapy of HIV-1 infection. Curr. Gene Ther. 2002, 2: 23-43.
75. Mautino, M.R., Keiser, N. and Morgan, R.A., Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev. J. Virol. 2001, 75: 3590-3599.
76. Mautino, M.R. and Morgan, R.A., Gene therapy of HIV-1 infection using lentiviral vectors expressing anti-HIV-1 genes. AIDS Patient Care STDS 2002, 16: 11-26.
77. Mautino, M.R. and Morgan, R.A., Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense. Gene Ther. 2002, 9: 421-431.
78. Miyoshi, H., Gene delivery to hematopoietic stem cells using lentiviral vectors. Meth. Mol. Biol. 2004, 246: 429-438.
79. + cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999, 283: 682-686.
80. Naldini, L., Blomer, U., Gallay P., Ory D., Mulligan, R., Gage, F.H., Verma, I.M. and Trono, D., In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272: 263-267.
81. Neff, T., Shotkoski, F. and Stamatoyannopoulos, G., Stem cell gene therapy, position effects and chromatin insulators. Stem Cells 1997, 15(1), 265-271.
82. Neville, M., Stutz, F., Lee, L., Davis, L.I. and Rosbash, M., The importin-beta family member Crm1p bridges the interaction between Rev and the nuclear pore complex during nuclear export. Curr. Biol. 1997, 7: 767-775.
83. Osborne, C.S., Pasceri, P., Singal, R., Sukonnik, T., Ginder, G.D. and Ellis, J., Amelioration of retroviral vector silencing in locus control region beta-globin-transgenic mice and transduced F9 embryonic cells. J. Virol. 1999, 73: 5490-5496.
84. Ott, M., Emiliani, S., Van Lint, C., Herbein, G., Lovett, J., Chirmule, N., McCloskey, T., Pahwa, S. and Verdin, E., Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 1997, 275: 1481-1485.
85. Pannell, D., Osborne, C.S., Yao, S., Sukonnik, T., Pasceri, P., Karaiskakis, A., Okano, M., Li, E., Lipshitz, H.D. and Ellis, J., Retrovirus vector silencing is de novo methylase independent and marked by a repressive histone code. EMBO J. 2000, 19: 5884-5894.
86. Pierson, T., McArthur, J. and Siliciano, R.F., Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu. Rev. Immunol. 2000, 18: 665-708.
87. Plavec, I., Agarwal, M., Ho, K.E., Pineda, M., Auten, J., Baker, J., Matsuzaki, H., Escaich, S., Bonyhadi, M. and Bohnlein, E., High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS. Gene Ther. 1997, 4: 128-139.
88. Pomerantz, R.J., Kuritzkes, D.R., de la Monte, S.M., Rota, T.R., Baker, A.S., Albert, D., Bor, D.H., Feldman, E.L., Schooley R.T. and Hirsch, M.S., Infection of the retina by human immunodeficiency virus type I. N. Engl. J. Med. 1987, 317: 1643-1647.
89. + T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat. Hum. Gene Ther. 1998, 9: 487-496.
90. + cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat. Hum. Gene Ther. 1999, 10: 2505-2514.
91. Ragheb, J.A., Couture, L., Mullen, C., Ridgway A. and Morgan, R.A., Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev. Hum Gene Ther. 1999, 10: 103-112.
92. Ramratnam, B., Mittler, J.E., Zhang, L., Boden, D., Hurley, A., Fang, F., Macken, C.A., Perelson, A.S., Markowitz, M. and Ho, D.D., The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat. Med. 2000, 6: 82-85.
93. Ramratnam, B., Ribeiro, R., He, T., Chung, C., Simon, V., Vanderhoeven, J., Hurley, A., Zhang, L., Perelson, A.S., Ho, D.D. and Markowitz, M., Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J. Acquir. Immun. Defic. Synd. 2004, 35: 33-37.
94. Ross, T.M., Bieniasz, P.D. and Cullen, B.R., Role of chemokine receptors in HIV-1 infection and pathogenesis. Adv. Virus Res. 1999, 52: 233-267.
95. Rossi, C., Balboni, P.G., Betti, M., Marconi, P.C., Bozzini, R., Grossi, M.P., Barbanti-Brodano, G. and Caputo, A., Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients. Gene Ther. 1997, 4: 1261-1269.
96. + T cells. J. Immunol. 1999, 162: 2427-2431.
97. Shaheen, F., Duan, L., Zhu, M., Bagasra, O. and Pomerantz, R.J., Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle. J. Virol. 1996, 70: 3392-3400.
98. Si-Mohamed, A., Kazatchkine, M.D., Heard, I., Goujon, C., Prazuck, T., Aymard, G., Cessot, G., Kuo, Y.H., Bernard, M.C., Diquet, B., Malkin, J.E., Gutmann, L. and Belec, L., Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J. Infect. Dis. 2000, 182: 112-122.
99. + T cells. Nat. Med. 2003, 9: 727-728.
100. Stevenson, M., Stanwick, T.L., Dempsey M.P. and Lamonica, C.A., HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 1990, 9: 1551-1560.
101. Strayer, D.S., SV40 as an effective gene transfer vector in vivo. J. Biol. Chem. 1996, 271: 24741-24746.
102. Strayer, D.S., Branco, F., Landre, J., BouHamdan, M., Shaheen, F. and Pomerantz, R.J., Combination genetic therapy to inhibit HIV-1. Mol. Ther. 2002, 5: 33-41.
103. Strayer, D.S., Kondo, R., Milano, J. and Duan, L.X., Use of SV40-based vectors to transduce foreign genes to normal human peripheral blood mononuclear cells. Gene Ther. 1997, 4: 219-225.
104. Strayer, D.S. and Milano, J., SV40 mediates stable gene transfer in vivo. Gene Ther. 1996, 3: 581-587.
105. Sun, L.Q., Ely, J.A., Gerlach, W. and Symonds, G., Anti-HIV ribozymes. Mol. Biotechnol. 1997, 7: 241-251.
106. Tewari, D., Notkins, A.L. and Zhou, P., Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene. J. Gene Med. 2003, 5: 182-189.
107. Tong-Starksen, S.E., Luciw, P.A. and Peterlin, B.M., Human immunodeficiency virus long terminal repeat responds to T cell activation signals. Proc. Natl. Acad. Sci. USA 1987, 84: 6845-6849.
108. Trono, D., Feinberg, M.B., and Baltimore, D., HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 1989, 59: 113-120.
109. + T lymphocytes by retroviral vectors expressing anti-HIV genes. J. Virol. 1995, 69: 4045-4052.
110. Weinberger, L.S., Schaffer, D.V. and Arkin, A.P., Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. J. Virol. 2003, 77: 10028-10036.
111. Wong, J.K., Hezareh, M., Gunthard, H.F., Havlir, D.V., Ignacio, C.C., Spina, C.A. and Richman, D.D., Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278: 1291-1295.
112. Yee, J.K., Miyanohara, A., LaPorte, P., Bouic, K., Burns, J.C. and Friedmann, T., A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. USA 1994, 91: 9564-9568.
113. Yu, M., Leavitt, M.C., Maruyama, M., Yamada, O., Young, D., Ho, A.D. and Wong-Staal, F., Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 1995, 92: 699-703.
114. Zagury D., Lachgar, A., Chains, V., Fall, L.S., Bernard, J., Zagury J.F., Bizzini, B., Gringeri, A., Santagostino, E., Rappaport, J., Feldman, M., Burny A. and Gallo, R.C., Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc. Natl. Acad. Sci. USA 1998, 95: 3851-3856.
115. Zauli, G., La Placa, M., Vignoli, M., Re, M.C., Gibellini, D., Furlini, G., Milani, D., Marchisio, M., Mazzoni, M. and Capitani, S., An autocrine loop of HIV type-1 Tat protein responsible for the improved survival/proliferation capacity of permanently Tat-transfected cells and required for optimal HIV-1 LTR transactivating activity. J. Acquir. Immun. Defic. Syndr. Hum. Retrovirol. 1995, 10: 306-316.
116. Zentilin, L., Qin, G., Tafuro, S., Dinauer, M.C., Baum, C. and Giacca, M., Variegation of retroviral vector gene expression in myeloid cells. Gene Ther. 2000, 7: 153-166.
117. Zhang, H., Dornadula, G., Beumont, M., Livornese, L. Jr., Van Uitert, B., Henning, K. and Pomerantz, R.J., Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N. Engl. J. Med. 1998, 339: 1803-1809.
118. Zhang, L., Ramratnam, B., Tenner-Racz, K., He, Y., Vesanen, M., Lewin, S., Talal, A., Racz, P., Perelson, A.S., Korber, B.T., Markowitz, M. and Ho, D.D., Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 1999, 340: 1605-1613.
119. Zhao, C., Strappe, P.M., Lever, A.M. and Franklin, R.J., Lentiviral vectors for gene delivery to normal and demyelinated white matter. Glia 2003, 42: 59-67.
120. Zocchi, M.R., Rubartelli, A., Morgavi, P. and Poggi, A., HIV-1 Tat inhibits human natural killer cell function by blocking L-type calcium channels. J. Immunol. 1998, 161: 2938-2943.